Preclinical evaluation of Amblyomin-X, a Kunitz-type protease inhibitor with antitumor activity

DOI: 10.1016/j.toxrep.2018.11.014

Keywords: Amblyomin-X, Kunitz-type inhibitor, Toxicity, Preclinical

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text